Citadel Advisors
INM icon

Citadel Advisors’s InMed Pharmaceuticals INM Stock Holding History

Citadel Advisors’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.4K Sell
26,084
-20,889
-44% -$23.1K ﹤0.01% 13215
2026
Q1 		$30.3K Buy
+46,973
New +$44.3K ﹤0.01% 12568
2024
Q4 		– Sell
-2,833
Closed -$13.3K – 14918
2024
Q3 		$13.3K Buy
2,833
+2,228
+368% +$11.4K ﹤0.01% 13067
2024
Q2 		$3.21K Sell
605
-31
-5% -$177 ﹤0.01% 13614
2024
Q1 		$4.48K Sell
636
-1,064
-63% -$7.82K ﹤0.01% 13813
2023
Q4 		$14.1K Buy
+1,700
New +$16.5K ﹤0.01% 12892
2022
Q3 		– Sell
-26
Closed -$6K – 13085
2022
Q2 		$6K Buy
+26
New +$9.95K ﹤0.01% 12664
2022
Q1 		– Sell
-22
Closed -$14K – 14069
2021
Q4 		$14K Sell
22
-14
-39% -$10.8K ﹤0.01% 13636
2021
Q3 		$31K Buy
36
+5
+16% +$5.96K ﹤0.01% 13560
2021
Q2 		$49K Sell
31
-3
-9% -$4.64K ﹤0.01% 13345
2021
Q1 		$57K Buy
+34
New +$72.9K ﹤0.01% 12838

Other funds holding INM

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UFM
Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Citadel Advisors's INM Position: Q2 2026 in Review

Citadel Advisors reduced its InMed Pharmaceuticals (INM) stake by 44% in Q2 2026, selling an estimated $23.1K and leaving 26,084 shares worth $40.4K. The position accounts for ﹤0.01% of the portfolio, ranked #13215.

Citadel Advisors first reported a position in INM in Q1 2021 and has held it in 11 quarters since. The position peaked at $57K in Q1 2021. 20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

  • Citadel Advisors held 26,084 shares of InMed Pharmaceuticals worth $40.4K as of Q2 2026.
  • Citadel Advisors sold 20,889 InMed Pharmaceuticals shares in Q2 2026, an estimated $23.1K.
  • InMed Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13215 holding.
  • Citadel Advisors first reported a position in InMed Pharmaceuticals in Q1 2021 and has held it in 11 quarters since.
  • Citadel Advisors's InMed Pharmaceuticals position peaked at $57K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.